Thermoanalytical studies of carbamazepine: hydration/dehydration, thermal decomposition, and solid phase transitions by Pinto, Mônia Aparecida Lemos et al.
*Correspondence: B. Ambrozini. Departamento de Química e Física Mo-
lecular, Instituto de Química de São Carlos, Universidade de São Paulo. Av. 
Trabalhador São-Carlense, 400, Caixa Postal 780, 13560-970, São Carlos, SP, 
Brasil. E-mail: biaambro@gmail.com
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 50, n. 4, oct./dec., 2014
http://dx.doi.org/10.1590/S1984-82502014000400023
Thermoanalytical studies of carbamazepine: hydration/
dehydration, thermal decomposition, and solid phase transitions
Mônia Aparecida Lemos Pinto, Beatriz Ambrozini*, Ana Paula Garcia Ferreira,  
Éder Tadeu Gomes Cavalheiro
Department of Chemistry and Molecular Physics, Institute of Chemistry of São Carlos,  
University of São Paulo, São Carlos, SP, Brazil
Carbamazepine (CBZ), a widely used anticonvulsant drug, can crystallize and exhibits four polymorphic 
forms and one dihydrate. Anhydrous CBZ can spontaneously absorb water and convert to the hydrate 
form whose different crystallinity leads to lower biological activity. The present study was concerned 
to the possibility of recovering the hydrated form by heating. The thermal behavior of spontaneously 
hydrated carbamazepine was investigated by TG/DTG-DTA and DSC in dynamic atmospheres of air 
and nitrogen, which revealed that the spontaneous hydration of this pharmaceutical resulted in a Form 
III hydrate with 1.5 water molecules. After dehydration, this anhydrous Form III converted to Form 
I, which melted and decomposed in a single event, releasing isocyanic acid, as shown by evolved gas 
analysis using TG-FTIR. Differential scanning calorimetry analyses revealed that Form III melted and 
crystallized as Form I, and that subsequent cooling cycles only generated Form I by crystallization. 
Solid state decomposition kinetic studies showed that there was no change in the substance after the 
elimination of water by heating to 120 °C. Activation energies of 98 ± 2 and 93 ± 2 kJ mol-1 were found 
for the hydrated and dried samples, respectively, and similar profiles of activation energy as a function 
of conversion factor were observed for these samples.
Uniterms: Carbamazepine/thermal analysis. Polymorphism. Hydrate. Dehydration.
A carbamazepina (CBZ) é um anticonvulsivante frequentemente utilizado no Brasil e em vários países. 
Ela apresenta quatro formas polimórficas e um diidrato. Todas as formas são ativas farmacologicamente, 
porém a Forma III é a preferível do ponto de vista farmacêutico, em função de suas propriedades físico-
químicas. Entretanto, essa forma é altamente higroscópica, podendo converter-se ao diidrato, menos ativo 
biologicamente. Nesse trabalho propõe-se avaliar o comportamento térmico da forma hidratada, visando 
à recuperação da forma ativa, por aquecimento. Para tanto, foi feito um estudo do comportamento térmico 
por TG/DTG-DTA e DSC em atmosfera dinâmica de ar e nitrogênio, que evidenciou hidratação espontânea 
da Forma III, gerando um hidrato contendo 1,5 moléculas de água. Essa forma sofre desidratação, seguida 
de fusão e conversão para a Forma I. Segue-se a decomposição em uma única etapa, na qual ocorre 
liberação do ácido isociânico, conforme análise de gases evolvidos, por termogravimetria acoplada ao 
infravermelho (TG-FTIR). Estudos por calorimetria exploratória diferencial mostraram que a Forma III 
se funde e se cristaliza imediatamente na Forma I, durante o aquecimento. A Forma I também se funde 
e ciclos de aquecimento/resfriamento posteriores evidenciaram que a substância se cristaliza apenas na 
Forma I por resfriamento. Estudos cinéticos da decomposição, em estado sólido, mostraram que não 
há alteração na substância pela eliminação da água por aquecimento, sendo determinados valores de 
energia de ativação da ordem de 98 ± 2 e 93 ± 2 kJ mol-1, respectivamente, para a amostra hidratada e 
submetida à secagem, assim como perfis semelhantes nas curvas de energia de ativação em função do 
fator de conversão.
Unitermos: Carbamazepina/análise térmica. Polimorfismo. Hidratação. Desidratação.
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INTRODUCTION
Carbamazepine (CBZ) (Figure 1), 5H-dibenz-
(b,f)azepine-5-carboxamide, is a white or almost white 
crystalline powder that is used as a first-generation 
anticonvulsant drug to treat epilepsy, trigeminal neuralgia, 
manic-depressive illness, and explosive aggression. The 
efficacy of CBZ was confirmed in the 1960s, when it was 
launched onto the commercial market (Liu et al., 2008; 
Ambrogi et al., 2007; Krongauz et al., 2007). When 
administered by the oral route, it presents a slow rate of 
absorption, which requires the use of a relatively large 
dose (Rose, Johnson, 1997; Dalkara, Karakurt, 2012).
At least four polymorphs and a dehydrate, as well as 
other solvates of CBZ, have been described in the literature 
(Qu, Louhi-Kultanen, Kallas, 2006; O’Mahony et al., 
2012). The melting points of the four polymorphs have 
been reported to be in the range 175-190 °C (Gosselin et 
al., 2003). The most stable known anhydrous form under 
room conditions is Form III. It is also known that in a 
humid environment, the anhydrates take up water and 
convert to the hydrates (Liu, Dang, Wei, 2012). Forms I 
and III of the drug constitute an enantiotropic pair, whose 
relative thermodynamic stability changes at 70 °C. Below 
this temperature, Form III is most stable, while above this 
temperature, Form I becomes more stable (McGregor et 
al., 2004; Behme, Brook, 1991; Lowes et al., 1987).
Hydrates are molecular complexes containing water 
molecules incorporated (usually stoichiometrically) into 
their crystal lattices (Han, Suryanarayanan, 1997). The 
water molecules of a hydrate can be released from the 
crystal lattice under drying conditions, such as heating. 
Most hydrate–anhydrate transformations are reversible and 
are influenced by temperature, relative humidity, particle 
size, and surface area. It is possible for the transformation 
to occur at room temperature as well as during drug 
processing, transportation, and storage. Evaluation of the 
hydration and dehydration behavior of pharmaceutical 
substances is important for the development of stable 
formulations, because the anhydrous and hydrated forms 
of a drug can show differences in their physicochemical 
characteristics. Properties including heat capacity, density, 
crystal structure, chemical stability, hygroscopicity, powder 
flow, and dissolution rate ultimately affect the bioavailability 
of a drug (Solon et al., 2010; Ono et al., 2002; McMahon et 
al., 1996; Qu, Louhi-Kultanen, Kallas, 2006).
In work by Xu et al. (2011), the pharmacokinetics 
of the polymorphic Forms I and III and the dihydrate of 
carbamazepine were evaluated in mice and compared to 
the behavior of these substances in dogs and humans. The 
absorption of Form III in mice was very similar to that 
observed for humans, and the pharmacokinetic properties 
and stability of the polymorph proved to be satisfactory. The 
P-monoclinic form Form III is considered more suitable for 
commercial formulations of carbamazepine, due to it higher 
bioavailability, compared to the other polymorphs.
Knowledge of the interconversion of the various 
polymorphic forms of CBZ is needed because the 
performance of this drug depends on the form that is 
present (Krahn, Mielck, 1987; Rustichelli et al., 2000; 
Kobayashi et al., 2000; Cabeza et al., 2007). However, 
information concerning the hydration/dehydration 
processes involved remains scarce. 
The most active form of carbamazepine is its 
anhydrous Form III, which is highly hygroscopic. It 
is therefore important to investigate the stability and 
thermal behavior of the spontaneously hydrated form, 
the regeneration of the active anhydrous Form III, and 
the polymorphic conversions involved in this process. 
Thermal analyses employing DSC and TG-DTA have 
been used previously to gain insight into the thermal 
behaviors of hydrated CBZ and Form III (Liu, Dang, 
Wei, 2012; McGregor et al., 2004; Han, Suryanarayanan, 
1997).Although Liu and co-workers (Liu, Dang, Wei, 
2012) recently described the thermal behavior of hydrated 
carbamazepine, considering dehydration, degradation, 
and kinetic data, to the best of our knowledge there have 
been no detailed studies of the degradation of CBZ and 
the formation of volatile products using TG-FTIR and 
DSC with heat-cool-heat cycles in order to elucidate the 
crystallization processes.
This work therefore describes an investigation 
of the thermal behavior of the spontaneously hydrated 
CBZ Form III, in terms of the dehydration process, 
formation of volatile degradation products, polymorphic 
interconversion, and the kinetics of dehydration and 
decomposition, in order to evaluate the possibility of 
recovering carbamazepine that becomes hydrated due to 
its storage under unsuitable conditions.
MATERIAL AND METHODS
Carbamazepine (pharmaceutical grade ≥ 99.0%, 
Sigma-Aldrich) was used without further purification and 
FIGURE 1 - Structure of carbamazepine.
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was stored under room conditions (T = 18-25 °C; humidity 
= 40-80%) for one year.
Simultaneous TG/DTG and DTA measurements 
were carried out using a Model SDT-Q600 analyzer (TA 
Instruments) with alumina sample holders (90 mL). The 
sample 6 mg was heated to a final temperature of 800 ºC 
at a rate of 10 °C min-1, under a flow of air (100 mL min-1). 
Temperature calibration of the apparatus employed a zinc 
standard, as recommended by the manufacturer.
Thermogravimetry (TG) was used to study the 
kinetics of CBZ thermal dehydration and decomposition, 
employing the Flynn-Wall-Ozawa model (Flynn, Wall, 
1996; Ozawa, 1970; Doyle, 1962). For the kinetic studies 
using spontaneously hydrated CBZ and samples of CBZ 
dried at 120 °C, TG analyses were performed at heating 
rates of were performed at heating rates of 2.5, 5.0, 10.0, 
and 15.0 min-1, under the same conditions described above. 
Guinesi et al. (2006) provided a detailed description of 
the theory and equations involved in this method. Data 
analysis was performed using Thermal Specialty Library 
v.1.4 software (TA Instruments).
DSC curves were obtained using sample masses of 
~2 mg, placed in covered aluminum pans with a central 
pinhole (ϕ = 0.7 mm) in the lid. The heating rate was 10 °C 
min-1, in a temperature interval of -40 to 194 ºC, under a 
flow of N2 at 25 mL min-1. The curves were obtained in 
heat-cool-heat cycle mode. A DSC-Q10 unit controlled by 
Thermal Advantage for Q-Series software (both from TA 
instruments) was used in these analyses. Calibrations of 
the equipment for temperature and enthalpy measurements 
were performed using indium metal (99.99% purity) as a 
standard, according to the manufacturer’s manual.
The TGA-FTIR experiments were performed using 
a TG-DSC 851 analyzer (Mettler-Toledo) coupled to a 
Nicolet iS10 FTIR spectrometer. The transfer line consisted 
of a stainless steel tube (120 cm length, 2 mm internal 
diameter), heated at a constant temperature of 200 °C. The 
FTIR measurements employed a DTGS detector with a 
gas cell heated at a constant temperature of 250 °C. The 
interferometer and the gas cell compartments were purged 
with highly purified N2 at a flow rate of 50 mL min
-1, and 
the heating rate was 10 °C min-1. The TG-DSC analyses 
were performed using a sample mass of 12 mg in alumina 
crucibles.
The carbon, hydrogen, and nitrogen contents of the 
samples were determined by elemental analysis, using a 
Model EA 1110 CHNS-O analyzer (CE Instruments).
X-ray powder diffraction patterns were obtained 
using a Rotaflex RU-200B X-ray diffractometer (Rigaku) 
employing CuKa radiation (a= 1.541 Å) and settings of 
50 kV and 100 mA.
RESULTS AND DISCUSSION
As commonly occurs with polymorphic systems, 
there has been much confusion about the naming of CBZ 
polymorphs. For the purposes of this article and for clarity, 
we have adopted the nomenclature described by Grzesiak 
et al. (2003).
Thermal behavior of spontaneously hydrated CBZ 
and anhydrous form III
In an air atmosphere, the thermal decomposition 
of spontaneously hydrate CBZ proceeds in three steps of 
mass loss, between 19 °C and 332 oC, following the TG/
DTG curves shown in Figure 2.
The first mass loss, which occurred in a single 
thermal event in the range 19-74 °C, corresponded to 
dehydration, with the loss of 1.5 water molecules. The 
experimental and calculated mass losses were 10.61% 
and 10.26% respectively. In order to confirm the existence 
of 1.5 molecules of hydration water in the sample of 
carbamazepine analyzed, it was subjected to elemental 
analysis (considering the contents of C, H, and N), before 
and after heating to 120 °C. The TG results showed that the 
first step of mass loss was completed and that no further 
decomposition occurred. Table I presents the comparative 
data obtained for the anhydrous sample and samples 
containing 1.5 and 2.0 water molecules.
It could be concluded that after heating, the anhydrous 
form was regenerated, without decomposition and 
preserving the original stoichiometry. The results also 
FIGURE 2 - TG (solid line), DTG (short dashed line), and DTA 
(dashed line) curves for carbamazepine heated in a dynamic air 
atmosphere (m = 6.186 mg).
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showed that the spontaneously hydrated sample contained 
only 1.5 molecules of hydration water per mol of CBZ, 
despite the fact that the literature suggests the existence of 
a dehydrate (Kobayashi et al., 2000). This can be explained 
by the occurrence of a spontaneous partial hydration, which 
then remained constant under ambient room conditions.
After dehydration, the second mass loss (79.8%), 
between 198 and 275 °C, was due to thermal decomposition 
of the anhydrous drug. The third mass loss (8.15%) in the 
range 275-332 °C, was attributed to the decomposition 
of residual carbonaceous material. A very small mass 
loss (1.2%) in the range 500-550 °C was related to the 
combustion of residual carbon.
The DTA curve obtained using an air atmosphere 
(Figure 2) exhibited six peaks and agreed with (and 
extended) the thermal data obtained from the TG/DTG 
curves. The first endothermic peak, at 67.1 °C, was 
attributed to dehydration, and the second endothermic 
peak, at 147.8 °C, was attributed to melting of the 
anhydrous polymorphic Form III (Liu, Dang, Wei, 2012; 
Kobayashi et al., 2000). The exothermic peak at 174.4 °C 
and the sharp endothermic peak at 184.9 °C corresponded 
to crystallization and to melting of the polymorphic Form 
I, respectively. The decomposition was accompanied by 
two endothermic peaks, at 262.4 and 314.8 °C, followed 
by an exothermic peak (at 530 ºC) attributed to combustion 
of the residual carbonaceous material.
The DSC curves obtained for the spontaneously 
hydrated carbamazepine using successive heating-cooling-
heating cycles are presented in Figure 3. During the first 
heating cycle, a broad endothermic peak appeared at 70.1 °C 
(Tonset = 58.5 ºC), corresponding to dehydration of the 
sample, in agreement with the TGA/DTG curve for the drug.
With further heating, a second endothermic signal was 
observed at ~ 173.5 °C (Tonset = 158.9 °C), corresponding 
to the melting of Form III of carbamazepine, which 
immediately crystallized as Form I, represented by the 
exothermic signal at 174.7 °C (Tonset = 173.8 °C). This was 
in agreement with the findings of Grzesiak et al. (2003).
Finally, a sharp endothermic peak at 191.3 °C 
(Tonset = 190.6 °C) corresponded to the melting of Form I 
(Grzesiak et al., 2003).
During the cooling step, a single thermal event 
was observed, represented by an exothermic peak at 
175.3 °C (Tonset = 178.2 °C), which was probably related to 
crystallization of the sample. Subsequent cooling to -40 °C 
did not reveal any other thermal events.
During the second heating step, no thermal event 
was observed in the -40 to 170 °C range. However, 
there was a sharp endothermic peak at 190.5 °C 
(Tonset = 187.8 °C) that coincided with the peak observed 
in the first heating cycle and was therefore related to the 
melting of Form I.
The enthalpy changes measured for thermal events 
observed during the heating-cooling-heating cycles can 
be summarized as follows:
Cycle 1: Dehydration of Form III:  ΔH = 74.35 kJ mol-1
 Melting of Form I: ΔH = 27.97 kJ mol-1
Cycle 2: Crystallization of Form I: ΔH = -22.37 kJ mol-1
Cycle 3: Melting of Form I: ΔH = 23.44 kJ mol-1
TABLE I - Experimental (exp) and calculated (calc) elemental composition of carbamazepine
Carbamazepine
Element / %, exp (calc)
C H N
C15H12N2O (anhydrous) 76.6 (76.1) 5.2 (5.1) 12.1 (11.8)
C15H12N2O. 1.5 H2O 67.7 (68.4) 7.1 (6.3) 10.7 (10.6)
C15H12N2O. 2 H2O 67.7 (66.1) 7.1 (5.9) 10.7 (10.2)
FIGURE 3 - Heat-cool-heat DSC curves for carbamazepine, 
obtained under an N2 atmosphere (m = 2.000 mg).
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Due to the fact that the carbamazepine Form 
III melting endotherm was followed by a subsequent 
Form I recrystallization exotherm, resolution of these 
two overlapping events was not possible using DSC. 
Consequently, it was not possible to measure the enthalpy 
changes involved in the Form III melting endotherm or 
the Form I crystallization in the first cycle (McGregor et 
al., 2004).
The melting of Form III followed by recrystallization 
of Form I was confirmed by heating the sample to 175 ºC 
in a glass tube and visually observing the changes.
In summary, it could be concluded that the sample 
used in this work was the spontaneously hydrated Form III 
of carbamazepine. When heated, this dehydrated to the 
anhydrous Form III in the solid phase, which then melted 
and converted to Form I by recrystallization. The Form I 
solid also showed melting, at a slightly higher temperature. 
Successive cooling and heating resulted in Form I in the 
solid and liquid phases, respectively. The present work 
therefore revealed that Form I was preferentially produced 
by cooling.
In order to confirm the phase transitions observed 
by DSC, a sample of the spontaneously hydrated 
CBZ was heated in an oven at 120 °C for 30 min. A 
second sample was heated at 196 °C for 30 min. X-ray 
diffraction analysis of the solids obtained after these 
thermal treatments revealed both were crystalline, as 
shown by the diffractograms (Figure 4). Specific peaks 
for spontaneously hydrated CBZ were observed at 
2q = 8.78, 12.15, 18.76, and 19.37 (Figure 4a). Form III 
showed diagnostic peaks at 2q = 15.36, 19.36, 24.82, and 
27.45 (Figure 4b). Specific peaks for Form I occurred at 
2q = 7.93, 9.40, 12.22, and 19.8 (Figure 4c).
Although the results were consistent with those 
described in the literature (Rustichelli et al., 2000; 
Kobayashi et al., 2000; Grzesiak et al., 2003), they 
revealed that CBZ Form III was converted to CBZ Form 
I significantly faster than previously reported. In earlier 
work, the times required were 9 h at 140 °C (Javadzadeh 
et al., 2009), 4 h at 140 °C (McMahon et al., 1996), and 
2 h at 170 °C (Behme, Brook, 1991). This time reduction 
included consideration of the melting of CBZ Form I, 
followed by its crystallization.
Evolved gas analysis
The gaseous products released during thermal 
decomposition of the CBZ hydrate were monitored 
by FTIR. In these experiments, the sample was again 
submitted to thermogravimetry, but under a dynamic 
nitrogen atmosphere. The resulting TG curve (not shown) 
FIGURE 4 - X-ray powder diffraction patterns for carbamazepine: 
(a) hydrated, (b) Form III, and (c) Form I.
was similar to that obtained in air. The FTIR spectra of the 
gaseous products evolved during the decomposition of the 
drug are presented in Figure 5.
FIGURE 5 - Infrared spectra of the gases released during the 
decomposition of carbamazepine in an N2 atmosphere.
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The FTIR spectra of the gaseous products evolved 
during the thermal decomposition of carbamazepine 
were indicative of the release of water, with intense 
evolution at 5.82 min (86.2 °C) associated with 
positive absorbance signals in the 3500-4000 cm-1 and 
1250-1750 cm-1 regions. Between 20.83 min (236.3 °C) 
and 40.60 min (434.0 °C), the evolution of isocyanic acid 
could be clearly observed, with signals at 3400, 2250, 
and 1000-500 cm-1.
At the end of the experiment, at 59.52 min 
(623.2 °C), small signals corresponding to water and 
CO2 were observed, which could be explained by the 
decomposition of carbonized material due to oxidation by 
traces of oxygen in the carrier gas. The gas phase spectra 
of water, CO2, and isocyanic acid matched those from the 
spectral library (OMNIC v.8.0, 2008).
The TG/DTG, DTA, and DSC curves, together with 
the FTIR spectra of the volatile decomposition products, 
were used to propose a pathway for the thermal behavior 
of spontaneously hydrated carbamazepine, as shown in 
Figure 6.
Although the proposed thermal pathway suggests 
that the decomposition occurred with the elimination of 
isocyanic acid (HNCO) and iminostilbene (C14H11N), 
only isocyanic acid could be positively identified in 
the evolved gas analysis using TG-FTIR. This could be 
explained by the condensation of iminostilbene, whose 
boiling point (220 °C) (Chemical Book, 2012) is the same 
as the transfer line temperature utilized (220 °C). The 
release of iminostilbene must have occurred, because the 
mass loss was almost complete in the first degradation 
step.
Thermal kinetics study
The aim of this study was to evaluate possible 
changes in the thermodynamic parameters of the 
carbamazepine decomposition processes due to 
either spontaneous hydration or dehydration by 
heating. Activation energies (Ea) and pre-exponential 
factors (log A) were measured for the dehydration and 
decomposition steps of the spontaneously hydrated 
sample, as well as for the decomposition of the sample 
heated to 120 °C (Table II). These values were obtained 
from the stable portions of the Ea vs. α plots (Vyazovkin 
et al., 2011).
From the data shown in Table II, it could be 
concluded that the of activation energies and log A factors 
for both the spontaneously hydrated sample and the sample 
heated to 120 °C were quite similar, confirming that these 
samples presented very similar characteristics. The TG 
curves obtained using different heating rates are presented 
in Figure 7.
CONCLUSIONS
The present investigation showed that Form III of 
anhydrous CBZ can become spontaneously hydrated, 
FIGURE 6 - Thermal pathway for the decomposition of 
carbamazepine.
TABLE II - Activation energies (Ea) and pre-exponential factors 
(log A) for hydrated and dried carbamazepine
Sample Event Ea / kJ mol-1
log A / 
min-1
CBZ 1.5 H2O
Dehydration 73 ± 2 11.3 ± 0.4
Decomposition 98 ± 2 9.3 ± 0.1
CBZ Decomposition 93 ± 2 8.6 ± 0.1
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FIGURE 7 - TG curves for spontaneously hydrated CBZ and 
CBZ heated at 120 ºC in an N2 atmosphere, using different 
heating rates: (a) 2.5; (b) 5.0; (c) 10.0; (d) 15.0 ºC min-1 
(m = 6.0 mg).
producing a 1.5 hydrate. The water molecules could be 
removed by heating the sample to 120 °C, without risk 
of decomposition of the active Form III. These findings 
were supported by the results of TG/DTG, DTA, X-ray 
diffraction, and thermal kinetics analyses.
A detailed pathway of the thermal behavior of the 
spontaneously hydrated sample is proposed, based on the 
TG-FTIR and DSC data and supported by X-ray diffraction 
analyses of the solids and the FTIR spectra obtained for the 
gases evolved during sample decomposition.
The melting of CBZ at temperatures near 200 °C 
seems to indicate that Form I is most stable. Form I was 
formed preferentially by cooling, under the conditions 
used here; any subsequent conversion observed during 
the cooling-heating cycles occurred after Form I was 
obtained.
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